Clinical Significance and Prognostic Value of Prenatal Diagnosis of Obliteration of the Cavum Septum Pellucidum
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 17, 2025
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into a condition called cavum septum pellucidum (CSP) obliteration, which is a finding that can be seen during a second-trimester ultrasound of a pregnant woman. The study aims to understand how common it is for fetuses with this condition to have other abnormalities and to analyze how these babies develop after birth. Essentially, researchers want to learn more about the potential effects of CSP obliteration on a child's future health and development.
To participate in this study, pregnant women need to be at least 18 years old and have received a diagnosis of CSP obliteration during their ultrasound between 19 to 22 weeks of pregnancy. There are no specific exclusions, meaning that if you meet the age and diagnosis criteria, you can take part. Women who join the study will help contribute to important research that could improve understanding and care for babies diagnosed with this condition. Participants will be closely monitored throughout the study, and their experiences will help doctors learn more about the implications of CSP obliteration for future pregnancies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant participants with a diagnosis of cavum septum pellucidum obliteration made at second-trimester morphologic ultrasound between 19+0 and 21+6 weeks
- • Age \> or = 18 years at the time of outpatient access
- • Acquisition of informed consent form, from the patient and minor
- • Patients followed at our center
- Exclusion Criteria:
- • None
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Gianluigi Pilu, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported